An interactive journey

through biopharmacy

This brochure contains interactive augmented

reality 3D content – accessible with the free
app Boehringer Ingelheim AR (iOS/Android).

105x148_BO Booklet 2019_EN.indd 1 15.03.2019 08:33:01

 2

This brochure contains augmented reality content.

Scan this QR code and download

the free app Boehringer
Ingelheim AR from the Apple
App store/iTunes (iOS) or the
Google Play store (Android).

Boehringer Ingelheim BIOPHARMACY V ienna 2019

105x148_BO Booklet 2019_EN.indd 2 15.03.2019 08:33:03

 3

After installing the app, focus your camera on

the images in the brochure to bring interactive
augmented reality 3D content to life, and to access
lots of additional information about development
and production at Boehringer Ingelheim in Vienna.

Boehringer Ingelheim BIOPHARMACY V ienna 2019

105x148_BO Booklet 2019_EN.indd 3 15.03.2019 08:33:05

 4

Welcome to the
Boehringer Ingelheim
World of Biopharmacy!
Pioneer and Top Provider
in the Biopharmaceutical Sector

Dr. Christian Eckermann

Head of Biopharma Austria

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 4 15.03.2019 08:33:09

 5

We produce high-quality pharmaceuticals

(biopharmaceuticals) with the help of living
cells. This enables us to offer therapies to
people around the world for diseases such
as multiple sclerosis and osteoporosis, or to
support blood thinning.

Would you like to know how many

atoms make up our largest active
substance molecule?
BIanca will tell you, if you scan the
image, using your mobile phone.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 5 15.03.2019 08:33:12

 6

The campus of Boehringer Ingelheim

in Austria

All the functions required to produce a

biopharmaceutical drug can be found at our
site in Vienna’s Meidling district – one of the
four global biopharmaceutical sites in the
group of companies.

In addition to biopharmaceuticals, it is also the

hub for the human pharmaceuticals and animal
health business for more than 30 countries and
Boehringer Ingelheim’s main cancer research
center.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 6 15.03.2019 08:33:16

 7

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 7 15.03.2019 08:33:31

 8

Teamwork is required when we

develop a new drug. Specialists
from development, production,
quality and many other fields work
together using state-of-the-art
technology to help patients around
the world.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 8 15.03.2019 08:33:32

 9

We also produce on behalf of other pharmaceutical

companies and are the world market leader!
We have launched a total of 31 biopharmaceuticals
onto the global market for ourselves and our
customers.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 9 15.03.2019 08:33:33

 10

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 10 15.03.2019 08:33:38

 11

The development and optimization of

the production process starts with a few
milliliters, which can be increased up to
15,000 liters in our large-scale plants, to
produce different active ingredients and
quantities. Flexibility and experience are
our greatest strengths.

In our largest fermenter (vessel for cell

proliferation) on site, we can produce up to one
quadrillion (a number with 15 zeros) cells.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 11 15.03.2019 08:33:43

 12

In biopharmacy, the focus is on perfection.

From the raw materials to the end products,
everything is carefully checked, analyzed and
documented, enabling us to ensure quality in
every phase of the process chain.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 12 15.03.2019 08:33:45

 13

Every year, we are subject to

approximately twelve inspections by
health authorities and customers from
all over the world, who inspect our
plants and operations very carefully.
This means an average of once a month!

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 13 15.03.2019 08:33:46

 14

Automated systems help us throughout the

entire development and production process
to manage data, generate visualizations and
help control the facilities.
Digitalisation also enables different systems
to communicate with each other and to
reduce manual interventions to a minimum.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 14 15.03.2019 08:33:48

 15

Our cell culture facility is equipped with a

fully digitized operation concept. The data
from approximately 20,000 metering points
are continuously available during the entire
production process.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 15 15.03.2019 08:33:50

 16

Boehringer Ingelheim maintains close

cooperations with universities,
colleges, start-up companies
and non-university research
institutions at home and
abroad with the aim of
always using state-of-
the-art technologies.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 16 15.03.2019 08:33:53

 17

We work together with 15 of

the top 20 pharmaceutical
companies worldwide.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 17 15.03.2019 08:33:56

 18

The Vienna location is developing on an

ongoing basis. In April 2017, a further milestone
was reached with the ground-breaking
ceremony for a cell culture plant.

The total investment of about 700 million euros

represents the largest single investment in over
130 years of company history, enabling us to
create 500 new jobs at the Vienna location.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 18 15.03.2019 08:33:57

 19

Vienna is the only location in the group of

companies where human pharmaceuticals are
produced both on the basis of microorganisms
(bacteria, yeasts) and with the aid of
mammalian cells.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 19 15.03.2019 08:33:57

 20

Boehringer Ingelheim is a family-owned

company that lives up to its social responsibility.

Therefore it is important for us to create a good

working atmosphere. Whether it is a company
day care facility, sports facilities or an employee
restaurant – we offer a variety of benefits, a
collaborative environment and a good work/life
balance.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 20 15.03.2019 08:33:58

 21

Continuous professional development is also a

key topic. Theoretical and practical content can
be perfectly adapted to the job in a real world
environment thanks to our own training facility.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 21 15.03.2019 08:34:00

 22

How long has Boehringer Ingelheim Vienna been doing

research in the field of biotechnology?
D) over 70 years N) over 30 years
C) over 50 years I) over 10 years

Which cells at Boehringer Ingelheim are not used to

produce drugs?
G) bacteria F) yeast
R) mammalian cells E) insect cells

What happens during the fermentation of a

biopharmaceutical drug?
L) cell proliferation and formation of the active ingredient
B) alcohol is produced
K) oxygen is formed
S) tablets are produced

How many new biopharmaceutical employees will be

taken on in Vienna by 2021?
A) 200 L) 500
U) 400 P) 700

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 22 15.03.2019 08:34:02

 23

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 23 15.03.2019 08:34:04

 24

Environmental protection, health, safety and

responsible business conduct are part of our DNA.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 24 15.03.2019 08:34:07

 25

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 25 15.03.2019 08:34:11

 26

Our thanks go to all those who have

supported us on our way so far – we
look forward to continuing our success
together in the future.

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 26 15.03.2019 08:34:15

 27

Legal notice:
Media owner, editor, publisher:
Boehringer Ingelheim RCV GmbH & Co KG,
A-1121 Vienna, Dr. Boehringer-Gasse 5-11,
Phone: + 43 (1) 801 05-0
Responsible for the content: Dr. Christian Eckermann
Editorial: Cornelia Wieser
Layout: Belinda Estl
Proofreader: Anneliese Krabina-Lindner
Translation: ALL Languages Alice Rabl GmbH, Wien
App programming: Martin Chiettini, Bobby Rajesh Malhotra,
Sebastian Pirch
Photographs: Adobe Stock, MirAlf Filmproduktion,
Rainer Mirau, Hubert Weiser
Campus map: Quadratmeter OEG
Visualisation virtual-reality-model production building:
©Architekturbüro Wolfgang Wildauer
Music clip: https://audiojungle.net/item/inspiring/9325839?s_rank=1
Speakers: Nicola Gold, Anneliese Krabina-Lindner
Motion Capturing: Anneliese Krabina-Lindner
CFD visualisation: Johannes Wutz

Copyright
© All rights reserved, in particular the right of reproduction (in whole
or in part). The brochure may not be reproduced or duplicated using
electronic systems without the written permission of Boehringer
Ingelheim RCV GmbH & Co KG.
January 2019

Website: www.boehringer-ingelheim.at
Job page: https://careers.boehringer-ingelheim.com/
Facebook: https://www.facebook.com/BoehringerAT
BioXcellence: https://www.bioxcellence.com/
Making More Health: www.makingmorehealth.org

Boehringer Ingelheim BIOPHARMACY VIENNA 2019

105x148_BO Booklet 2019_EN.indd 27 15.03.2019 08:34:19

 Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer-Gasse 5-11
A-1121 Vienna
Phone: + 43 (1) 801 05-0
Fax: + 43 (1) 804 08 23
www.boehringer-ingelheim.com

105x148_BO Booklet 2019_EN.indd 28 15.03.2019 08:34:19